switching from dulaglutide to semaglutide Simulation scenarios for 0.5 or 1.0 mg dulaglutide to semaglutide conversion dulaglutide

You may be suitable for treatment if you: Are aged 18 years or over Have a Body Mass Index (BMI) of 30 or above Have a BMI of 27 or above with eligible weight-related health conditions Are looking for additional support with weight management Have found it difficult to achieve sufficient weight loss through lifestyle changes alone All patients must complete a clinical assessment before treatment can be prescribed

R., et al

I think of using these medications in three groups of patients

Other weight loss Options Low Dose Naltrexone Low Dose Naltrexone (LDN) has shown promise in aiding weight loss through several mechanisms, even though its exact process is not fully understood

Potential Risks and Safety Considerations The principal thyroid-related safety concern with GLP-1RAs arises from rodent studies demonstrating C-cell hyperplasia and medullary thyroid carcinoma (MTC) following chronic exposure [47,60]

Consult your provider